Sodium 3-(2H-benzotriazol-2-yl)-5-sec-butyl-4-hydroxybenzenesulfonate

Endpoint summary

Description of key information

Sodium 3(2H-benzotriazol-2-yl)-5-sec-butyl-4-hydroxybenzenesulfonate was tested for acute toxicity by oral and dermal application to the rat according to OECD guideline 401 and 402. The LD50 (oral) was greater than 5000 mg/kg bw and the LD50 (dermal) was greater than 2000 mg/kg bw.

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion

Dose descriptor:

LD50

Value:

5 000 mg/kg bw

Acute toxicity: via dermal route

Endpoint conclusion

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Additional information

Acute toxicity oral:

The test article sodium 3(2H-benzotriazol-2-yl)-5-sec-butyl-4-hydroxybenzenesulfonate was administered to rats of both sexes by oral gavage, at a dose of 5000 mg/kg according to OECD giudeline 401.

The following death rate was observed: 10 % at 5000 mg/kg.

The acute oral LD50 of test item in 10 rats (5 males/5 females) of both sexes, observed over a period of 15 days, was estimated to be greater than 5000 mg/kg.

Acute toxicity dermal:

The test article sodium 3(2H-benzotriazol-2-yl)-5-sec-butyl-4-hydroxybenzenesulfonate was applied to the skin of rats of both sexes by oral gavage for 24 hours at a dose of 2000 mg/kg according to OECD giudeline 402.

The following death rate was observed: 0 % at 2000 mg/kg.

Therefore, the LD50 of test item was estimated to be greater than 2000 mg/kg.

Justification for classification or non-classification

Based on all available information, the test substance is not classified with regard to acute toxicity according to Directive 67/548/EEC (DSD) and to Regulation (EC) No 1272/2008 (CLP), respectively.